Press Releases

03 May 2019

Acacia Pharma Receives Complete Response Letter from FDA for BARHEMSYS®

25 April 2019

Positive Phase 3 BARHEMSYS® Rescue Treatment Data to be Presented at the Annual Congress of Enhanced Recovery and Perioperative Medicine

27 February 2019

Results for the year ended 31 December 2018

28 January 2019

Editorial in Anesthesiology on Positive Data for BARHEMSYS™ PONV Rescue Treatment

22 January 2019

Supportive Cardiac Safety Data for BARHEMSYS™

12 December 2018

Positive Clinical Results for APD403 in CINV Published in Supportive Care in Cancer

07 December 2018

New BARHEMSYS™ PDUFA date confirmed for 5 May 2019

21 November 2018

Positive BARHEMSYS™ Rescue Treatment Data Published in Anesthesiology

06 November 2018

Acacia Pharma Resubmits BARHEMSYS™ New Drug Application

06 November 2018

Unaudited Results for the nine months to 30 September 2018

15 October 2018

Further update on FDA regulatory review of BARHEMSYS™ 

08 October 2018

Update on FDA regulatory review of BARHEMSYS™

14 September 2018

Positive BARHEMSYS™ Phase 3 Treatment Data Published in Anesthesia & Analgesia

07 September 2018

Interim Results for the First Half Year 2018

09 July 2018

Operating Update for the First Half 2018

02 July 2018

$30 Million Credit Facility with Hercules Technology Growth Capital Secured to Support Intended Commercialisation of BARHEMSYS™ in the US

11 April 2018

US Commercial Operations for BARHEMSYS™ (formerly BAREMSIS®) Expanded Four Key Appointments

15 March 2018

BARHEMSYS™ (formerly BAREMSIS®) Prevents Post-Operative Nausea & Vomiting In High-Risk Patients (published in Anesthesiology)

04 January 2018

FDA Acceptance Of NDA Filing For BAREMSIS® For The Management Of PONV

13 February 2017

Positive Results From 4th And Final Pivotal Phase 3 Trial Of BAREMSIS® For Rescue Treatment Of PONV

12 August 2016

Positive Results From Pivotal Phase 3 Trial Of BAREMSIS® For The Treatment Of PONV

21 March 2016

Initiation Of Second Pivotal Phase 3 Treatment Trial With BAREMSIS® In PONV

05 January 2016

Positive Results From Second Pivotal Phase 3 Prophylaxis Study Of BAREMSIS® In PONV

03 December 2015

Dr Patrick Vink To Succeed Ian Kent As Non-Executive Chairman

06 May 2015

Positive Results From Phase 2 Study With APD403 In CINV